Clinical trial NCT04051307: Dual Vaccine Trial in Myeloproliferative Neoplasms
Official title: Dual Vaccine Trial in Myeloproliferative Neoplasms
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Polycythemia Vera
Essential Thrombocythemia
Lead sponsor: Herlev Hospital
Sponsor class: OTHER
First posted: 2019-08-09
Enrollment: 9
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A phase I-II study in patients with mutated MPN by vaccinating with PD-L1 and Aginase1 peptides with Montanide ISA-51 as adjuvant, to monitor the immunological response to vaccination and subsequently safety, toxicity and clinical effect.


Eligibility criteria: Inclusion Criteria:

* 1. Diagnosis of essential thrombocythemia or Polycythemia Vera, according to the WHO criteria123,124 2. Age ≥18 years 3. Performance status ≤ 2 (ECOG-scale) 4. Expected survival \> 3 months 5. Sufficient bone marrow function 6. Creatinine \< 2.5 upper normal limit, i.e. \< 300 µmol/l 7. Sufficient liver function, i.e.

  1. ALAT \< 2.5 upper normal limit, i.e. ALAT \<112 U/l
  2. Bilirubin \< 30 U/l 8. For women: Agreement to use contraceptive methods with a failure rate of \< 1% per year during the treatment period and for at least 120 days after the last treatment.

     9. For men: Agreement to use contraceptive measures and agreement to refrain from donating sperm.

     Exclusion criteria
     1. Other malignancies in the medical history excluding basal cell carcinoma. Patients cured for another malignant disease with no sign of relapse five years after ended treatment is allowed to enter the protocol.
     2. Significant medical condition per investigators judgement e.g. severe Asthma/COPD, poorly regulated heart condition, insulin dependent diabetes mellitus.
     3. Acute or chronic viral or bacterial infection e.g. HIV, hepatitis or tuberculosis
     4. Serious known allergies or earlier anaphylactic reactions.
     5. Known sensibility to Montanide ISA-51
     6. Any active autoimmune diseases e.g. autoimmune neutropenia, thrombocytopenia or hemolytic anemia, systemic lupus erythematosus, scleroderma, myasthenia gravis, autoimmune glomerulonephritis, autoimmune adrenal deficiency, autoimmune thyroiditis etc.
     7. Pregnant and breastfeeding women.
     8. Fertile women not using secure contraception with a failure rate less than \< 1%
     9. Patients taking immune suppressive medications incl. systemic corticosteroids and methotrexate at the time of enrollment
     10. Psychiatric disorders that per investigator judgment could influence compliance.
     11. Treatment with other experimental drugs
     12. Treatment with other anti-cancer drugs - except IFN-a, hydroxyurea or anagrelide.
     13. Treatment with ruxolitinib.
     14. Treatment with chemotherapy or immune therapy (excluding IFN-a, hydroxyurea or anagrelide) within the last 28 days.

Primary outcomes:
measure: Immune response
timeFrame: 1 year
Secondary outcomes:
measure: Adverse events evaluated by CTCAE v. 5.0
timeFrame: 1 year
measure: Clinical response
timeFrame: 10 year
Other outcomes:
Locations:
city: Herlev
country: Denmark
facility: Herlev Hospital
state: Capital Region
city: Herlev
country: Denmark
facility: National Center for Cancer Immune Therapy (CCIT-DK)
Study officials:
affiliation: CENTER FOR CANCER IMMUNE THERAPY, CCIT-DK
name: Jacob H Grauslund, MD
role: PRINCIPAL_INVESTIGATOR
References: